Triferic (Ferric Pyrophosphate Citrate) Administered Orally for the Treatment of Iron Refractory Iron Deficiency Anemia (IRIDA)
A study for patients with Iron Refractory Iron-Deficiency Anemia (IRIDA) using study drug Triferic
Sponsor: Rockwell Medical, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ9720
U.S. Govt. ID: NCT02905981
Contact: Katherine Ender: 212-305-9770 /
Additional Study Information: The main purpose of the study is to find out whether Triferic, when taken by mouth (orally) with Shohls solution, is safe and effective for the treatment of Iron Refractory Iron-Deficiency Anemia (IRIDA). The study drug, ferric pyrophosphate citrate (FPC), is also called Triferic. It is an iron salt that has been approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin (prevention of anemia/low red blood cell counts) in adults with chronic kidney disease on hemodialysis. It has not yet been tested in patients with iron-refractory iron deficiency anemia (IRIDA), and so its use is considered experimental (investigational) in this study.
This study is closed
Katherine Ender, MD
Do You Qualify?
Have you been diagnosed with Iron Refractory Iron-Deficiency Anemia? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Katherine Ender